Kairos Pharma reports positive Phase 2 interim PFS data; median PFS 17.7 vs 2 months
Kairos Pharma reported Phase 2 interim data showing median progression-free survival of 17.7 months for ENV-105 plus apalutamide vs 2 months for apalutamide alone (P=0.0008). The trial protocol was modified to enroll patients earlier and expand the eligible population, with trial completion targeted for Q4 2027. ENV-105 is a CD105 antibody aimed at reversing drug resistance.
How this was made
The 30-second read
Why it matters
The interim data suggest a significant efficacy advantage, which could accelerate the trial timeline and improve valuation.
Market read
Positive trial data for a biotech can trigger immediate price moves and influence sector sentiment.
What to watch
Potential regulatory hurdles and competition from other CD105 therapies could temper upside.
Background
Kairos Pharma filed an 8‑K reporting interim Phase 2 data for its ENV-105 antibody combined with apalutamide.
Ticker impact
Kairos Pharma disclosed statistically significant Phase 2 interim efficacy data showing median PFS of 17.7 months with ENV-105 plus apalutamide versus 2 months with apalutamide alone.
upward pressure as the market incorporates the strong efficacy data
The data represent a material clinical milestone that can materially improve valuation expectations.
Market effects
May boost sentiment for CD105 antibody platforms and related oncology biotech peers.
Limited to U.S. biotech sector; no broader regional effect.
Modest global relevance, primarily affecting biotech investors.
Counterpoint
If the Phase 2 data do not translate to Phase 3 success, the rally could be short-lived.
Key entities
- companyKairos Pharma
Biopharmaceutical company developing ENV-105.
- drugENV-105
First‑in‑class CD105 antibody targeting drug resistance.
